Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

Background Trials of monoclonal antibodies that target various forms of amyloid at different
stages of Alzheimer's disease have had mixed results. Methods We tested solanezumab …

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying
patients who could benefit from these treatments becomes critical. In this study, we …

Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the
Alzheimer disease (AD) process. Aβ accumulation begins 15–20 years before clinical …

Objective We examined whether plasma β-amyloid (Aβ) 42/Aβ40, as measured by a high-
precision assay, accurately diagnosed brain amyloidosis using amyloid PET or CSF p …

Importance Positron emission tomography (PET) imaging now allows in vivo visualization of
both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau …

Importance Alzheimer disease (AD) pathology starts with a prolonged phase of β-amyloid
(Aβ) accumulation without symptoms. The duration of this phase differs greatly among …